Rebecca Taub sold $17M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 46,463 shares at an average of $355.32, traded Aug 11, 2025, filed Aug 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$16.5M at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001423898-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | MOption exercise Common Stock10b5-1 | +3,200 | $9.45 | $30k | 464,244 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Common Stock10b5-1 | -2,980 | $350.18 | $1.0M | 461,264 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Common Stock10b5-1 | -220 | $351.02 | $77k | 461,044 | Aug 13, 2025 |
| Aug 12, 2025 | MOption exercise Common Stock10b5-1 | +43,263 | $9.45 | $409k | 504,307 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -3,580 | $350.87 | $1.3M | 500,727 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -2,870 | $351.60 | $1.0M | 497,857 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,175 | $352.45 | $414k | 496,682 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -4,587 | $354.04 | $1.6M | 492,095 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -6,479 | $354.97 | $2.3M | 485,616 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -5,752 | $355.95 | $2.0M | 479,864 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -4,864 | $356.88 | $1.7M | 475,000 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -6,715 | $357.85 | $2.4M | 468,285 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -6,541 | $358.81 | $2.3M | 461,744 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -700 | $359.71 | $252k | 461,044 | Aug 13, 2025 |
| Aug 11, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,200 | $0.00 | $0 | 43,263 | Aug 13, 2025 |
| Aug 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -43,263 | $0.00 | $0 | 0 | Aug 13, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 45Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $8.0M 16,575 shares | -86% | |
| 50Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.2M 7,279 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.0M 7,616 shares | -6% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $25M 68,618 shares | +36% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $37M 97,065 shares | +50% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $480k 1,304 shares | -12% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $3.7M 10,000 shares | -79% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $17M 46,808 shares | -25% | |
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $48M 129,172 shares | -41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.